Figure 2.
A combination of multimodal screening showed potential targets of EVI1 in AML cells. (A) Venn diagram of ChIP-seq data using anti-FLAG antibody, showing FLAG-EVI1 binding regions. Two 3× FLAG-tagged EVI1-AML samples and a sample from 32D-cl3 murine hematopoietic progenitor cells where FLAG-tag was knocked in to the 3′-end of the Mecom locus. (B) Database for Annotation, Visualization and Integrated Discovery (DAVID) analysis showing AML-specific EVI1-binding regions. (C) A model of RNA-seq experiments. Genes upregulated at both early and late points after EVI1 introduction were chosen for further analysis. (D) Venn diagram of genes with EVI1-binding (ChIP-seq), upregulation after EVI1 transduction (RNA-seq), and positive correlation between EVI1 expression (microarray). (E) The list of genes in the common population of Figure 2D. (F) A scheme of the screening assay using DsRed. (G) Relative enrichment of DsRed+ cells expressing shRNA against each gene through days 3 and 10, adjusted by the shLuciferase control. Significance was examined in comparison with the shLuciferase control. (H) qPCR showing the relative expression of Evi1, Erg, and Ccnd1 in GFPhigh and GFPlow AML cells. Mean ± SD. ∗P < .05.

A combination of multimodal screening showed potential targets of EVI1 in AML cells. (A) Venn diagram of ChIP-seq data using anti-FLAG antibody, showing FLAG-EVI1 binding regions. Two 3× FLAG-tagged EVI1-AML samples and a sample from 32D-cl3 murine hematopoietic progenitor cells where FLAG-tag was knocked in to the 3′-end of the Mecom locus. (B) Database for Annotation, Visualization and Integrated Discovery (DAVID) analysis showing AML-specific EVI1-binding regions. (C) A model of RNA-seq experiments. Genes upregulated at both early and late points after EVI1 introduction were chosen for further analysis. (D) Venn diagram of genes with EVI1-binding (ChIP-seq), upregulation after EVI1 transduction (RNA-seq), and positive correlation between EVI1 expression (microarray). (E) The list of genes in the common population of Figure 2D. (F) A scheme of the screening assay using DsRed. (G) Relative enrichment of DsRed+ cells expressing shRNA against each gene through days 3 and 10, adjusted by the shLuciferase control. Significance was examined in comparison with the shLuciferase control. (H) qPCR showing the relative expression of Evi1, Erg, and Ccnd1 in GFPhigh and GFPlow AML cells. Mean ± SD. ∗P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal